JP2006518750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006518750A5 JP2006518750A5 JP2006503763A JP2006503763A JP2006518750A5 JP 2006518750 A5 JP2006518750 A5 JP 2006518750A5 JP 2006503763 A JP2006503763 A JP 2006503763A JP 2006503763 A JP2006503763 A JP 2006503763A JP 2006518750 A5 JP2006518750 A5 JP 2006518750A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- functionally equivalent
- inhibitor
- fragment
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims 17
- 108090001123 antibodies Proteins 0.000 claims 17
- 239000004074 complement inhibitor Substances 0.000 claims 7
- 108010009575 CD55 Antigens Proteins 0.000 claims 2
- 108010027437 compstatin Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 101700010660 C1S Proteins 0.000 claims 1
- 101710035625 C1sa Proteins 0.000 claims 1
- 101710035626 C1sb Proteins 0.000 claims 1
- 102100007826 C4BPA Human genes 0.000 claims 1
- 101700051748 C4BPA Proteins 0.000 claims 1
- 102100003281 CD59 Human genes 0.000 claims 1
- 101700073334 CD59 Proteins 0.000 claims 1
- 102100019404 CDSN Human genes 0.000 claims 1
- 101700062689 CDSN Proteins 0.000 claims 1
- 108090000197 Clusterin Proteins 0.000 claims 1
- 102000003780 Clusterin Human genes 0.000 claims 1
- 108010005563 Complement C1 Inhibitor Protein Proteins 0.000 claims 1
- 102000005911 Complement C1 Inhibitor Protein Human genes 0.000 claims 1
- 102000016550 Complement Factor H Human genes 0.000 claims 1
- 108010053085 Complement Factor H Proteins 0.000 claims 1
- 101710005864 HI_0216 Proteins 0.000 claims 1
- 108010085169 Lysine Carboxypeptidase Proteins 0.000 claims 1
- 101710005865 MPN_201 Proteins 0.000 claims 1
- 101710005862 MPN_285 Proteins 0.000 claims 1
- 101710005861 MPN_289 Proteins 0.000 claims 1
- 101710005860 MPN_290 Proteins 0.000 claims 1
- 101710029070 MPN_343 Proteins 0.000 claims 1
- 101710005841 MPN_365 Proteins 0.000 claims 1
- 101710005863 MPN_615 Proteins 0.000 claims 1
- 101710005859 MPN_638 Proteins 0.000 claims 1
- 102000005919 Membrane Cofactor Protein Human genes 0.000 claims 1
- 108010005662 Membrane Cofactor Protein Proteins 0.000 claims 1
- 102100009661 VTN Human genes 0.000 claims 1
- 108010031318 Vitronectin Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000000295 complement Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- -1 factor I Proteins 0.000 claims 1
- 102000037240 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000005085 meconium aspiration syndrome Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 101700083974 prrB Proteins 0.000 claims 1
Claims (10)
- 胎便吸引症候群の治療または予防のための医薬の製造のための補体阻害剤の使用。
- 補体阻害剤がコンプスタチン（compstatin）およびその機能的アナログ、Ｃ１阻害剤、Ｃ１ｑ阻害剤、Ｃ１ｓ阻害剤、ｓＣＲ１およびそのアナログ、抗−Ｃ５抗体およびその機能的に等価なフラグメント、抗−Ｃ５ａ抗体およびその機能的に等価なフラグメント、抗−Ｃ５ａ受容体抗体およびその機能的に等価なフラグメント、抗−Ｃ３ａ抗体およびその機能的に等価なフラグメント、抗−Ｃ３ａ受容体抗体およびその機能的に等価なフラグメント、抗−Ｃ６抗体およびその機能的に等価なフラグメント、抗−Ｃ７抗体およびその機能的に等価なフラグメント、抗−Ｃ８抗体およびその機能的に等価なフラグメント、抗−Ｃ９抗体およびその機能的に等価なフラグメント、抗−プロペルジン（properdin）抗体およびその機能的に等価なフラグメント、融合蛋白メンブランコファクタープロテイン、崩壊促進因子（ＤＡＦ）、Ｃ４ｂｐ、Ｈ因子、Ｉ因子、カルボキシペプチダーゼＮ、ビトロネクチン（Ｓ蛋白）、クルステリン（clusterin）およびＣＤ５９からなる群から選択される請求項１記載の使用。
- 補体阻害剤が抗体またはその機能的に等価なフラグメントである請求項１記載の使用。
- 抗体が抗−Ｄ因子抗体である請求項３記載の使用。
- 抗体が抗−プロペルジン抗体およびその機能的に等価なフラグメント、抗−Ｃ５抗体およびその機能的に等価なフラグメント、および抗−Ｃ５ａ抗体およびその機能的に等価なフラグメントからなる群から選択される請求項３記載の使用。
- 補体阻害剤が第２補体経路の成分を阻害する請求項１〜５のいずれか１項記載の使用。
- 補体阻害剤が１日につき体重１ｋｇあたり約３〜５０ｍｇの投与量で投与される請求項１〜６のいずれか１項記載の使用。
- 補体阻害剤および１以上の医薬上許容されるアジュバント、担体、賦形剤または希釈剤を含んでなる組成物。
- 補体阻害剤が請求項２〜７のいずれか１項記載のものである請求項８記載の組成物。
- ２以上の補体阻害剤を含んでなる請求項８または９記載の組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44904503P | 2003-02-21 | 2003-02-21 | |
| PCT/US2004/005143 WO2004075838A2 (en) | 2003-02-21 | 2004-02-20 | Method and compositions for the treatment of meconium aspiration syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006518750A JP2006518750A (ja) | 2006-08-17 |
| JP2006518750A5 true JP2006518750A5 (ja) | 2007-04-12 |
Family
ID=32927491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503763A Pending JP2006518750A (ja) | 2003-02-21 | 2004-02-20 | 胎便吸引症候群の治療のための方法および組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20070065433A1 (ja) |
| EP (1) | EP1594541A4 (ja) |
| JP (1) | JP2006518750A (ja) |
| WO (1) | WO2004075838A2 (ja) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005002513A2 (en) * | 2003-06-16 | 2005-01-13 | The Brigham And Women's Hospital, Inc. | C1q complement inhibitors and methods of use thereof |
| JP5137053B2 (ja) * | 2004-02-10 | 2013-02-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬 |
| WO2006128006A1 (en) * | 2005-05-26 | 2006-11-30 | The Regents Of The University Of Colorado | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| AU2008214359B2 (en) * | 2007-02-05 | 2014-01-16 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
| CN101668773B (zh) | 2007-03-14 | 2016-08-31 | 亚力史制药公司 | 人工程化抗b因子抗体 |
| WO2008156365A1 (en) | 2007-06-21 | 2008-12-24 | Pantarhei Bioscience B.V. | Treatment of meconium aspiration syndrome with estrogens |
| AU2008313276A1 (en) * | 2007-10-16 | 2009-04-23 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Device and method for identification of meconium in amniotic fluid |
| US8937046B2 (en) * | 2008-09-22 | 2015-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Modulating the alternative complement pathway |
| RU2012102021A (ru) | 2009-06-23 | 2013-07-27 | Алексион Фармасьютикалз, Инк. | Биспецифические антитела, которые связываются с белками комплемента |
| EP2453906A4 (en) | 2009-07-02 | 2014-01-15 | Musc Found For Res Dev | METHOD FOR STIMULATING THE LIVER REGENERATION |
| SG11201403416TA (en) * | 2011-12-21 | 2014-07-30 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
| US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
| RS62243B9 (sr) | 2012-11-15 | 2022-11-30 | Apellis Pharmaceuticals Inc | Analozi kompstatina sa produženim trajanjem dejstva i njihove kompozicije i postupci |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| EP3359555B1 (en) | 2015-10-07 | 2023-12-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| GB2553252B (en) | 2016-01-20 | 2019-07-31 | Vitrisa Therapeutics Inc | Aptamers that block the catalytic cleft of complement Factor D |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| CN116059313A (zh) | 2017-04-07 | 2023-05-05 | 阿佩利斯制药有限公司 | 给药方案以及相关组合物和方法 |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| CA3177415A1 (en) * | 2020-05-21 | 2021-11-25 | Kevin Peters | Methods of treating acute respiratory distress syndrome with activators of tie-2 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6013619A (en) * | 1988-01-06 | 2000-01-11 | The Scripps Research Institute | Pulmonary surfactants and therapeutic uses, including pulmonary lavage |
| US5514598A (en) * | 1993-11-30 | 1996-05-07 | Doody; Michael | Prenatal detection of meconium |
| US5562077B1 (en) * | 1995-04-04 | 2000-09-05 | Joseph Schultz | Method and apparatus for ventilation and aspiration |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6044284A (en) * | 1998-10-08 | 2000-03-28 | Leonard I. Eisenfeld | Apparatus and method for measuring the concentration of meconium in amniotic fluid |
| EP1152759A2 (en) * | 1999-02-09 | 2001-11-14 | 3-Dimensional Pharmaceuticals, Inc. | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
| JP2001089391A (ja) * | 1999-09-16 | 2001-04-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Ｉｒｄｓおよびａｌｉの治療用の製薬的組成物、その使用、およびそれを有する製品 |
| NZ526720A (en) * | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
-
2004
- 2004-02-20 EP EP04713391A patent/EP1594541A4/en not_active Withdrawn
- 2004-02-20 US US10/546,253 patent/US20070065433A1/en not_active Abandoned
- 2004-02-20 WO PCT/US2004/005143 patent/WO2004075838A2/en active Application Filing
- 2004-02-20 JP JP2006503763A patent/JP2006518750A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006518750A5 (ja) | ||
| US7183381B2 (en) | Composition of lactoferrin related peptides and uses thereof | |
| US10945962B2 (en) | Controlled-release peptide compositions and uses thereof | |
| JP2018052983A5 (ja) | ||
| Furci et al. | Inhibition of HIV-1 infection by human α-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae | |
| JP2009528369A (ja) | 補体活性を抑制することによる同種移植片の生存の延長 | |
| JP2008518090A5 (ja) | ||
| JP2011518179A5 (ja) | ||
| JP5190518B2 (ja) | 免疫関連疾患を予防および治療するための組成物 | |
| JP2005515214A5 (ja) | ||
| JP2023510864A (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の持続型結合体の肺疾患の治療的使用 | |
| Harfouch et al. | Therapeutic approaches for COVID 19: Challenges and successes | |
| JP2011522864A5 (ja) | ||
| Howe et al. | Pulmonary haemorrhage, pulmonary infarction, and the lupus anticoagulant. | |
| WO2015104596A1 (en) | Vasoactive intestinal peptide | |
| JP2006508099A5 (ja) | ||
| Ishimitsu et al. | Interferon gamma attenuates hypertensive renal injury in salt-sensitive Dahl rats. | |
| Ayala et al. | Blockade of apoptosis as a rational therapeutic strategy for the treatment of sepsis | |
| Huang et al. | Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41 | |
| WO2017054831A1 (en) | Use of human derived immunosuppressive proteins and peptides as medicaments | |
| US20230151107A1 (en) | Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19 | |
| JP2007500693A (ja) | 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法 | |
| JP2010511706A5 (ja) | ||
| CA2141951C (en) | Inhibition of retrovirus infection | |
| WO2018091679A1 (en) | Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes |